{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:13:25Z","timestamp":1790050405300,"version":"4.0.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>SARS-CoV-2 pandemic has presented a significant threat to global health and the economy, necessitating urgent efforts to develop effective antiviral drugs. The main protease (3CLpro) of SARS-CoV-2 is a critical target for antiviral therapy due to its essential role in viral replication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In order to find new structural types of 3CLpro inhibitors to facilitate the solution to the problem of new virus resistance. Six potential pharmacologically bioactive compounds were identified by utilizing structure-based virtual screening and <jats:italic>in vitro<\/jats:italic> assays from the Topscience database containing 10 million compounds.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results and Discussion<\/jats:title><jats:p>Among these, compounds 34 and 36 exhibited potent inhibitory activity with IC<jats:sub>50<\/jats:sub> values of 6.12 \u00b1 0.42\u00a0\u03bcM and 4.47 \u00b1 0.39\u00a0\u03bcM, respectively. To elucidate their binding mechanisms with 3CLpro, all-atom molecular dynamics (MD) simulations were conducted. Principal component analysis (PCA), free energy landscapes (FEL) and dynamic cross-correlation maps (DCCM) revealed that the binding of compounds 34 and 36 to 3CLpro significantly enhanced the structural stability of 3CLpro, reducing conformational flexibility and internal motions. The results of protein-ligand interaction showed that compounds 34 and 36 formed strong and stable interactions to key residues at active site of 3CLpro with different binding modes from S-217622. And HOMO-LUMO gap and molecular electrostatic potential distribution revealed the quantum chemical properties of compounds 34 and 36. These findings suggested that compounds 34 and 36 can be as novel SARS-CoV-2 3CLpro inhibitors and promising lead-like drug candidates for developing COVID-19 treatments.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1494953","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T09:00:59Z","timestamp":1730278859000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Identification of novel SARS-CoV-2 3CLpro inhibitors by molecular docking, in vitro assays, molecular dynamics simulations and DFT analyses"],"prefix":"10.3389","volume":"15","author":[{"given":"Keli","family":"Zong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaochun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyuan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingzhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"W257","DOI":"10.1093\/nar\/gky318","article-title":"ProTox-II: a webserver for the prediction of toxicity of chemicals","volume":"46","author":"Banerjee","year":"2018","journal-title":"Nucleic. acids. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"W513","DOI":"10.1093\/nar\/gkae303","article-title":"ProTox 3.0: a webserver for the prediction of toxicity of chemicals","volume":"52","author":"Banerjee","year":"2024","journal-title":"Nucleic. acids. Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 \u2014 final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"6055","DOI":"10.1038\/s41467-021-26239-2","article-title":"Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19","volume":"12","author":"Boras","year":"2021","journal-title":"Nat. Commun."},{"key":"B5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.pulmoe.2020.07.003","article-title":"Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review","volume":"27","author":"Cortegiani","year":"2021","journal-title":"Pulmonology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Sci. Am. Assoc. Adv. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"101069","DOI":"10.1016\/j.bbrep.2021.101069","article-title":"Peptide inhibitors against SARS-CoV-2 2\u2032-O-methyltransferase involved in RNA capping: a computational approach","volume":"27","author":"Dutta","year":"2021","journal-title":"Biochem. Biophys. Rep."},{"key":"B9","article-title":"Gaussian 16 Rev. C.01","author":"Frisch","year":"2016"},{"key":"B10","doi-asserted-by":"publisher","first-page":"130589","DOI":"10.1016\/j.molstruc.2021.130589","article-title":"Synthesis, crystal structure, vibrational spectral investigation, intermolecular interactions, chemical reactivity, NLO properties and molecular docking analysis on (E)-N-(4-nitrobenzylidene)-3-chlorobenzenamine: a combined experimental and theoretical study","volume":"1240","author":"Guerroudj","year":"2021","journal-title":"J. Mol. Struct."},{"key":"B11","doi-asserted-by":"publisher","first-page":"14767","DOI":"10.1021\/acsomega.0c01643","article-title":"Theoretical study on CL-20-based cocrystal energetic compounds in an external electric field","volume":"5","author":"Hao","year":"2020","journal-title":"ACS Omega"},{"key":"B12","doi-asserted-by":"publisher","first-page":"12800","DOI":"10.1080\/07391102.2021.1977181","article-title":"In silico and in vitro assays reveal potential inhibitors against 3CLpro main protease of SARS-CoV-2","volume":"40","author":"Iype","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B13","doi-asserted-by":"publisher","first-page":"39477","DOI":"10.1039\/c8ra08198k","article-title":"Multiple 3D-QSAR modeling, e-pharmacophore, molecular docking, and in vitro study to explore novel AChE inhibitors","volume":"8","author":"Jana","year":"2018","journal-title":"RSC Adv."},{"key":"B14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1016\/S1473-3099(23)00813-7","article-title":"Virological characteristics of the SARS-CoV-2 JN.1 variant","volume":"24","author":"Kaku","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges","volume":"55","author":"Lai","year":"2020","journal-title":"Int. J. Antimicrob. Agents."},{"key":"B18","unstructured":"Sobtop 1.0 dev3.1\n            LuT.\n          2022"},{"key":"B19","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/jcc.22885","article-title":"Multiwfn: a multifunctional wavefunction analyzer","volume":"33","author":"Lu","year":"2012","journal-title":"J. Comput. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","article-title":"ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J. Chem. Theory Comput."},{"key":"B21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.medj.2024.01.013","article-title":"Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19","volume":"5","author":"Mao","year":"2024","journal-title":"Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"622898","DOI":"10.3389\/fchem.2021.622898","article-title":"Structural basis of potential inhibitors targeting SARS-CoV-2 main protease","volume":"9","author":"Mengist","year":"2021","journal-title":"Front. Chem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s42003-020-01577-x","article-title":"Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents","volume":"4","author":"Mody","year":"2021","journal-title":"Commun. Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1093\/cid\/ciab875","article-title":"Remdesivir treatment in hospitalized patients with coronavirus disease 2019 (COVID-19): a comparative analysis of in-hospital all-cause mortality in a large multicenter observational cohort","volume":"75","author":"Mozaffari","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e0069722","DOI":"10.1128\/aac.00697-22","article-title":"A randomized phase 2\/3 study of Ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part","volume":"66","author":"Mukae","year":"2022","journal-title":"Antimicrob. Agents. Chemother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/cid\/ciac933","article-title":"Efficacy and safety of Ensitrelvir in patients with mild-to-moderate coronavirus disease 2019: the phase 2b part of a randomized, placebo-controlled, phase 2\/3 study","volume":"76","author":"Mukae","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1093\/cid\/ciac443","article-title":"Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients","volume":"76","author":"Najjar-Debbiny","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"165878","DOI":"10.1016\/j.bbadis.2020.165878","article-title":"Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach","volume":"1866","author":"Naqvi","year":"2020","journal-title":"Biochimica biophysica acta. Mol. basis Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"12237","DOI":"10.1021\/acs.jmedchem.3c00810","article-title":"Alkyne as a latent warhead to covalently target SARS-CoV-2 main protease","volume":"66","author":"Ngo","year":"2023","journal-title":"J. Med. Chem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"129655","DOI":"10.1016\/j.ijbiomac.2024.129655","article-title":"Identification of antiviral phytochemicals from cranberry as potential inhibitors of SARS-CoV-2 main protease (Mpro)","volume":"261","author":"Pillai","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.drudis.2020.01.015","article-title":"Recent discovery and development of inhibitors targeting coronaviruses","volume":"25","author":"Pillaiyar","year":"2020","journal-title":"Drug Discov. Today."},{"key":"B32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/bs.pmch.2021.01.004","article-title":"Use of molecular docking computational tools in drug discovery","volume":"60","author":"Stanzione","year":"2021","journal-title":"Prog. Med. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e0084023","DOI":"10.1128\/aac.00840-23","article-title":"Evaluation of in vitro antiviral activity of SARS-CoV-2 Mpro inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions","volume":"67","author":"Tong","year":"2023","journal-title":"Antimicrob. Agents. Chemother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet British Ed."},{"key":"B36","first-page":"388","article-title":"Identification of potential hit compounds for Dengue virus NS2B\/NS3 protease inhibitors by combining virtual screening and binding free energy calculations","volume":"30","author":"Wichapong","year":"2013","journal-title":"Trop. Biomed."},{"key":"B37","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","article-title":"Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review","volume":"324","author":"Wiersinga","year":"2020","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"B38","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.1038\/s41586-020-2202-3","article-title":"Author Correction: a new coronavirus associated with human respiratory disease in China","volume":"580","author":"Wu","year":"2020","journal-title":"Nat. Lond."},{"key":"B39","doi-asserted-by":"publisher","first-page":"23555","DOI":"10.1039\/d3cp03828a","article-title":"The molecular mechanism of non-covalent inhibitor Wu-04 targeting SARS-CoV-2 3CLpro and computational evaluation of its effectiveness against mainstream coronaviruses","volume":"25","author":"Wu","year":"2023","journal-title":"Phys. Chem. Chem. Phys. PCCP"},{"key":"B40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S1473-3099(20)30911-7","article-title":"The place for remdesivir in COVID-19 treatment","volume":"21","author":"Young","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3390\/ijms17020246","article-title":"Systems pharmacology in small molecular drug discovery","volume":"17","author":"Zhou","year":"2016","journal-title":"Int. J. Mol. Sci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1494953\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T09:01:02Z","timestamp":1730278862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1494953\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":41,"alternative-id":["10.3389\/fphar.2024.1494953"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1494953","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"article-number":"1494953"}}